Amicus Therapeutics (NASDAQ: FOLD) is one of 111 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Amicus Therapeutics to similar businesses based off the strength of its valuation, analyst recommendations, dividends, institutional ownership, risk, earnings and profitability.

Institutional & Insider Ownership

43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.4% of Amicus Therapeutics shares are held by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Amicus Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics -1,279.88% -61.25% -20.08%
Amicus Therapeutics Competitors -3,504.60% -46.51% -7.90%

Earnings and Valuation

This table compares Amicus Therapeutics and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Amicus Therapeutics $16.28 million -$186.93 million -9.42
Amicus Therapeutics Competitors $7.97 billion $2.54 billion 0.78

Amicus Therapeutics’ competitors have higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently the more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for Amicus Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics 0 0 6 0 3.00
Amicus Therapeutics Competitors 935 3744 5954 164 2.50

Amicus Therapeutics presently has a consensus price target of $14.58, suggesting a potential upside of 5.29%. All “Pharmaceuticals” companies have a potential upside of 23.59%. Given Amicus Therapeutics’ competitors higher probable upside, analysts clearly believe Amicus Therapeutics has less favorable growth aspects than its competitors.

Risk and Volatility

Amicus Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Amicus Therapeutics’ competitors have a beta of 0.86, meaning that their average stock price is 14% less volatile than the S&P 500.


Amicus Therapeutics competitors beat Amicus Therapeutics on 8 of the 12 factors compared.

About Amicus Therapeutics

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with's FREE daily email newsletter.